
Robert Davis is the chairman and chief executive of Merck & Co., the New Jersey drugmaker known as MSD outside the United States and Canada. A former chief financial officer at Baxter, he joined Merck in the same job in 2014, became CEO in July 2021 and added the chairman's role in December 2022.
Under Davis, Merck has come to lean on one cancer drug for nearly half of its sales. Merck's own yearly tables show Keytruda growing from 35.3% of its sales in 2021, the year Robert Davis became chief executive, to 48.7% in 2025. Everything else the company sold grew only 5.75% over those four years.
Who Is the CEO of Merck?
Robert Davis is the CEO of Merck, a job he has held since 1 July 2021, when he also joined the board. Davis added the chairman's seat on 1 December 2022, so the same person runs the company and leads the board that oversees it.
Davis runs Merck & Co. of Rahway in New Jersey, and its shares trade on the New York Stock Exchange under the ticker MRK. Phemex lists MRK among its TradFi futures, contracts that follow the price of a stock or a metal without you owning it.
His work reaches past Merck. Davis chairs the board of the Pharmaceutical Research and Manufacturers of America, the group known as PhRMA. He's also a vice president of the International Federation of Pharmaceutical Manufacturers and Associations and a director of Duke Energy, where he chairs the finance and risk management committee.
Davis also serves on two nonprofit boards. One is Project HOPE, which supports health workers. The other is Catalyst, which works for equal access to corporate leadership for women.
How Much of Merck's Revenue Is Keytruda?
Keytruda brought in nearly half of Merck's revenue in 2025, about $31.7 billion of $65.0 billion in sales, according to Merck's full-year 2025 results. Keytruda is Merck's brand name for pembrolizumab, a cancer medicine. From 2025 the same line also counts Keytruda Qlex, a version injected under the skin.
Qlex added only $40 million of the 2025 total, so the original drug drove almost all of that year's growth.
Each share below is Keytruda's sales divided by total sales, both from Merck's own releases.
|
Period
|
Merck sales and Keytruda ($ million)
|
Keytruda share
|
|
2020 (restated after Organon)
|
41,518 and 14,380
|
34.6%
|
|
2021
|
48,704 and 17,186
|
35.3%
|
|
2022
|
59,283 and 20,937
|
35.3%
|
|
2023
|
60,115 and 25,011
|
41.6%
|
|
2024
|
64,168 and 29,482
|
45.9%
|
|
2025 (with Keytruda Qlex)
|
65,011 and 31,680
|
48.7%
|
|
Q3 2026, one quarter
|
18,085 and 8,601
|
47.6%
|
As a percentage of Merck's sales, Keytruda's share rose every year from 2021 to 2025 except 2022, when it held flat. The 2025 share was the highest of the full years 2019 to 2025. In 2019 Keytruda made up about 24% of sales that still included Organon's businesses.
Merck spun off its women's health, biosimilars and established brands businesses as Organon & Co. on 2 June 2021, according to Merck's full-year 2021 release. That's why the 2020 row uses Merck's restated total.
The rest of Merck barely grew. Everything other than Keytruda brought in $31.5 billion in 2021 and $33.3 billion in 2025, while Keytruda's own sales rose 84%. In between, sales outside Keytruda peaked in 2022 at $38.3 billion, lifted by Merck's oral COVID-19 medicine Lagevrio. They fell back as Lagevrio faded and Gardasil vaccine sales dropped 39% in 2025.
If you trade MRK, that makes Keytruda news close to Merck news.
Robert Davis's Career at Eli Lilly, Baxter and Merck
Davis spent 14 years at Eli Lilly and Company before he joined Baxter in 2004, according to his Merck biography.
Davis's last job at Baxter was corporate vice president and president of its medical products business. Earlier at Baxter he had run the renal business as its president, and he had also served as chief financial officer and treasurer.
After a decade at Baxter, Davis moved to Merck as chief financial officer in 2014. The job also covered corporate strategy and business development. In 2016 Merck added information technology and procurement to his remit, and the combined group became Global Services. That made Davis executive vice president of Global Services as well as CFO. Seven years after he arrived, Merck named him president in April 2021.
As president, Davis oversaw the company's operating divisions, from its research laboratories to manufacturing and animal health. He became chief executive three months later.
His biography names finance and general-management jobs before 2021, so Davis came to the top of a research-led drugmaker from the business side.
Davis holds a law degree from Northwestern University's Pritzker School of Law and an MBA from its Kellogg Graduate School of Management. His bachelor's degree, in finance, came from Miami University.
What Did Merck Report for the Third Quarter of 2026?
Merck reported its third-quarter 2026 results on 29 October 2026, with sales up 5% from a year earlier to $18.1 billion. "Our science-led strategy is transforming our business," Davis said in the release.
|
Line
|
Third quarter 2026
|
Change from Q3 2025
|
|
Total sales
|
$18.1 billion
|
+5%
|
|
Keytruda and Keytruda Qlex
|
$8.6 billion
|
+6%
|
|
Gardasil vaccines
|
$2.0 billion
|
+14%
|
|
Winrevair
|
$694 million
|
+93%
|
|
Animal Health
|
$1.7 billion
|
+4%
|
|
Earnings per share (GAAP)
|
$2.04
|
-12%
|
|
Earnings per share (non-GAAP)
|
$2.49
|
-3%
|
Keytruda's share of the quarter's sales came to 47.6%, a little above the 47.2% of the same quarter in 2025. Keytruda Qlex added $830 million of that total.
Januvia and Janumet went the other way. Their sales fell 39% to $380 million, which Merck put down mainly to generic competition after the drugs lost US market exclusivity.
GAAP earnings follow standard US accounting rules, and Merck's non-GAAP figure leaves out certain items. Both include a one-time charge of $0.12 a share for a global license agreement with SciBrunch Therapeutics. Merck also narrowed its forecast for 2026 sales to between $66.8 billion and $67.3 billion, which raised the midpoint.
Merck's 2026 earnings forecast also carries the cost of its deals. It expects non-GAAP earnings of $2.77 to $2.82 a share for the year, a range that includes about $6 a share of one-time charges for buying Cidara and Terns and for the SciBrunch license. Davis closed his comments with "I'm increasingly confident in our ability to deliver long-term value for patients and shareholders."
For an MRK trade, the dates that matter most are Merck's quarterly releases and regulators' rulings on its drugs. Both are on the list of stock-specific risks in what traders should know before trading TradFi futures.
Where Can You Trade MRK Futures on Phemex?
Phemex lists an MRK/USDT perpetual, a futures contract with no expiry date that tracks Merck's share price and settles in USDT. It opened on 31 August 2026, and each contract covers one MRK share.
Open interest, the count of MRK contracts still open, never resets at a settlement date. That's the main way open interest differs in perpetual and quarterly futures, since a quarterly contract's open interest falls to zero when it settles.
You can go long if you expect MRK to rise or short if you expect it to fall. You never own the shares, so the contract pays no dividend and carries no vote.
Long and short positions swap payments every eight hours through funding rates, the mechanism meant to keep a perpetual's price close to the asset it follows.
The contract also trades on weekends, when the New York Stock Exchange is closed. Spreads can be wider and order books thinner in those hours, which can make price moves sharper.
Merck's shares fell about 3.6% to $132.81 at the mid-November close, and the MRK perpetual's daily bar fell by about as much. That was in line with the median move across Phemex's TradFi perpetuals that day.
Futures use leverage, and a leveraged position is closed automatically if losses push its margin below a set minimum. The MRK contract allows up to 20x, and at that level a move of about 5% against you equals your whole margin.
Frequently Asked Questions
Who is the president of Merck?
Robert Davis is Merck's president as well as its chairman and CEO. He signed Merck's third-quarter 2026 report to the SEC under all three titles. Merck's executive team page lists five executive vice presidents who each run a division as its president.
When did Robert Davis become CEO of Merck?
Davis took over as Merck's chief executive on 1 July 2021 and became chairman of the board on 1 December 2022. He had joined the company as its chief financial officer in 2014.
Is Robert M. Davis the same person as Rob Davis?
Yes. Merck's earnings releases name its chairman and chief executive Robert M. Davis, and the company's leadership page calls him Rob Davis.
Disclaimer: This article is for informational purposes only and is not financial advice. Cryptocurrency trading involves substantial risk. Always do your own research before making investment decisions.
